SEC Form 4 · accession 0001640455-18-000039
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberlee C Drapkin
Officer — CFO and Treasurer
Period of report
Mar 8, 2018
Accepted (ET)
Mar 12, 2018 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 8, 2018 | M | 3,759 | $0.48 | A | 5,267 | D | |
| Common StockF2 | Mar 8, 2018 | S | 5,267 | $25.01 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.48 | Mar 8, 2018 | M | 3,759 | D | — | Jan 27, 2024 | Common Stock | 3,759 | 3,016 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
- F2Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.